Some studies demonstrated that in cardiovascular and pulmonary diseases, Cav-1 could inhibit eNOS activity, thereby affecting normal angiogenesis and barrier function (Schubert et al., 2002; Sonveaux et al., 2004; Oliveira and Minshall, 2018). Here, CAV1 is linked to lung disorder.